National Patient Advocate Foundation

National Patient Advocate Foundation
Name	National Patient Advocate Foundation
Founded	1996
Type	Nonprofit organization
Headquarters	Washington, D.C.
Focus	Patient advocacy, health policy, chronic illness

National Patient Advocate Foundation is a nonprofit organization that advocates for patients with chronic, complex, and life-threatening illnesses in the United States. The organization works at the intersection of health policy, patient services, and community engagement to influence legislation, provide direct support, and convene stakeholders. It operates alongside allied organizations and coalitions to advance access to care, affordability, and patient-centered policy solutions.

History

The organization was founded in 1996 amid shifts in health policy debates involving the Health Maintenance Organization Act, Medicare Part D, and state-level insurance reforms. Early activity aligned with advocacy efforts surrounding the Patient Protection and Affordable Care Act, the passage of which influenced subsequent campaigns. Over the 2000s and 2010s the group engaged with debates stemming from rulings such as King v. Burwell and legislative initiatives like the 21st Century Cures Act and Cancer Moonshot. The organization has participated in coalitions that responded to emergencies including the Hurricane Katrina recovery and the COVID-19 pandemic. It has collaborated with other advocacy and patient-centered groups during rulemaking at agencies such as the Centers for Medicare & Medicaid Services and the Food and Drug Administration.

Mission and Programs

The foundation's stated mission emphasizes representation of patients in policy forums, service delivery, and education. Programs include patient navigation and case management informed by models used by Susan G. Komen for the Cure and the American Cancer Society. Service lines reflect continuity with efforts led by groups such as the National Coalition for Cancer Survivorship and the American Kidney Fund. Educational initiatives have mirrored approaches from institutions like the Robert Wood Johnson Foundation and the Kaiser Family Foundation to inform public deliberations. The foundation runs assistance programs resonant with the work of the National Alliance on Mental Illness and the American Diabetes Association to address cost-related nonadherence, specialty drug access, and clinical trial participation.

Advocacy and Policy Initiatives

Advocacy priorities include prescription drug pricing, insurance coverage protections, and access to specialty therapies. Campaigns have targeted legislation such as proposals modeled on the Medicare Modernization Act and state affordability boards similar to those in Colorado. The foundation has submitted comments during rulemaking processes led by the Department of Health and Human Services and engaged with congressional committees including the United States Senate Committee on Finance and the United States House Committee on Energy and Commerce. It has joined coalitions with organizations like the AARP, the American Civil Liberties Union, and the March of Dimes on issues spanning patient privacy under the Health Insurance Portability and Accountability Act and biomarker-driven care tied to approvals by the National Institutes of Health and the European Medicines Agency. The foundation has also weighed in on value frameworks championed by entities such as the Institute for Clinical and Economic Review.

Partnerships and Funding

The foundation partners with advocacy organizations, academic centers, and industry stakeholders. Notable collaborations have included alliances with the American Society of Clinical Oncology, the Leukemia & Lymphoma Society, and the Multiple Myeloma Research Foundation. Funding streams comprise philanthropic grants from foundations like the Gates Foundation and the Wellcome Trust as well as corporate contributions from biopharmaceutical firms represented by trade groups such as the Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization. The organization has received project-specific funding that involved multi-stakeholder initiatives with institutions such as the Brookings Institution and the Commonwealth Fund.

Governance and Leadership

Governance is administered by a board of directors with leadership roles comparable to boards at the American Heart Association and the Susan Thompson Buffett Foundation. Executive leadership has engaged with policy leaders from agencies such as the Office of Management and Budget and the Centers for Disease Control and Prevention. The foundation has hosted advisory panels that include clinicians and researchers from institutions like Johns Hopkins University, Massachusetts General Hospital, and the Mayo Clinic. It maintains ethics and conflict-of-interest policies informed by standards used by entities such as the National Institutes of Health and the Association of American Medical Colleges.

Impact and Criticism

Supporters cite the foundation's role in patient navigation, policy representation, and legislative wins affecting drug coverage and cost-sharing, paralleling impacts credited to groups like the Patient-Centered Outcomes Research Institute and the Federal Emergency Management Agency in disaster-related health access. Critics have raised concerns about funding relationships with pharmaceutical companies and the potential for influence, similar to scrutiny faced by organizations such as the American Medical Association and the Academy of Managed Care Pharmacy. Debates have occurred in forums like the Senate Finance Committee hearings and in analyses by investigative outlets similar to ProPublica and The New York Times. The organization has responded by emphasizing transparency policies aligned with guidance from the Open Government Partnership and governance recommendations from the Nonprofit Quarterly.

Category:Non-profit organizations based in Washington, D.C.